Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Giulia Rivoli, Germana Beltrami, Anna M. Raiola, Carole Paley, Marcello Riggi, Alida Dominietto, Emanuele Angelucci

Blood (2022) 140 (Supplement 1): 13271–13272.

DOI: https://doi.org/10.1182/blood-2022-158985

Published: 2022

Journal Articles

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Blood (2022) 140 (Supplement 1): 10514–10516.

DOI: https://doi.org/10.1182/blood-2022-162853

Published: 2022

Journal Articles

Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program

Eric Deconinck, Madhu Anant, David Manteigas, Carole Paley, Marcello Riggi, Marco Herling, Emanuele Angelucci

Blood (2022) 140 (Supplement 1): 8115–8116.

DOI: https://doi.org/10.1182/blood-2022-159942

Published: 2022

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Uwe Platzbecker, Emanuele Angelucci, Pau Montesinos, Roberto Massimo Lemoli, Alexandros Spyridonidis, Tariq I. Mughal, Carole Paley, Marcello Riggi, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 11710–11712.

DOI: https://doi.org/10.1182/blood-2022-160127

Published: 2022

Journal Articles

A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Giuliano Filippini Velazquez, Myriam Labopin, Johanna Tischer, Emanuele Angelucci, Alexander D. Kulagin, Piero Galieni, Arancha Bermúdez, Claude-Eric Bulabois, Nicolaus Kröger, José Luis Díez-Martin, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7744–7746.

DOI: https://doi.org/10.1182/blood-2022-160229

Published: 2022

Journal Articles

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Blood (2022) 140 (Supplement 1): 7734–7737.

DOI: https://doi.org/10.1182/blood-2022-168601

Published: 2022

Journal Articles

Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality

Sabrina Giammarco, Carmen Di Grazia, Anna Maria Raiola, Stefania Bregante, Riccardo Varaldo, Francesca Gualandi, Simona Sica, Patrizia Chiusolo, Federica Sora, Luca Laurenti, Elisabetta Metafuni, Andrea Bacigalupo, Emanuele Angelucci

Blood (2021) 138 (Supplement 1): 2867.

DOI: https://doi.org/10.1182/blood-2021-147903

Published: 2021

Journal Articles

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Blood (2021) 138 (Supplement 1): 3057.

DOI: https://doi.org/10.1182/blood-2021-146188

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Blood (2021) 138 (Supplement 1): 3890.

DOI: https://doi.org/10.1182/blood-2021-151087

Published: 2021

Journal Articles

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, Pietro Pioltelli, Mutlu Arat, Ibrahim Yakoub-Agha, Aleksandr D. Kulagin, Emanuele Angelucci, Hakan Ozdogu, Antonio Risitano, Fabio Ciceri, Zubeyde Nur Ozkurt, Jaime Sanz, Eolia Brissot, Zinaida Peric, Sebastian Giebel, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 1841.

DOI: https://doi.org/10.1182/blood-2021-144558

Published: 2021

Journal Articles

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Blood (2021) 138 (Supplement 1): 3954.

DOI: https://doi.org/10.1182/blood-2021-147684

Published: 2021

Journal Articles

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Uwe Platzbecker, Emanuele Angelucci, Pau Montesinos, Roberto M. Lemoni, Alexandros Spyridonidis, Joaquín Casariego, Tariq I. Mughal, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 5032.

DOI: https://doi.org/10.1182/blood-2021-145099

Published: 2021

Journal Articles

A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients

Blood (2020) 136 (Supplement 1): 23–24.

DOI: https://doi.org/10.1182/blood-2020-138775

Published: 2020

Journal Articles

Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis

Blood (2020) 136 (Supplement 1): 11–12.

DOI: https://doi.org/10.1182/blood-2020-136302

Published: 2020

Journal Articles

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 26–27.

DOI: https://doi.org/10.1182/blood-2020-137099

Published: 2020

Journal Articles

Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis

Blood (2020) 136 (Supplement 1): 38–39.

DOI: https://doi.org/10.1182/blood-2020-134173

Published: 2020

Journal Articles

Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT

Joshua A Fein, MD, Roni Shouval, MD PhD, Myriam Labopin, MD, Fabio Ciceri, MD, Emanuele Angelucci, MD, Didier Blaise, MD, Johanna Tischer, William Arcese, MD PhD, Yener Koc, MD, Benedetto Bruno, MD, Jose L. Diez-Martin, MD PhD, Stella Santarone, MD, Simona Sica, MD PhD, Jurjen Versluis, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2020) 136 (Supplement 1): 24–25.

DOI: https://doi.org/10.1182/blood-2020-139519

Published: 2020

Journal Articles

Bone Marrow Multiparametric Magnetic Resonance Imaging with Texture Analysis for Follow-up of Advanced Stage Myelofibrosis after Transplantation

Massimiliano Gambella, MD, Federico Zaottini, MD, Stefania Bregante, MD, Riccardo Picasso, MD, Emanuele Barabino, MD, Carlo Martinoli, MD, Emanuele Angelucci, MD

Blood (2020) 136 (Supplement 1): 3–4.

DOI: https://doi.org/10.1182/blood-2020-141099

Published: 2020

Journal Articles

Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia

Alida Dominietto, MD, Stefano Vagge, MD, Susanta Hui, PhD, Carmen Di Grazia, MD, Teresa Lamparelli, MD, Stefania Bregante, MD, Anna Maria Raiola, MD, Riccardo Varaldo, MD, Francesca Gualandi, MD, Renzo Corvò, MD, Emanuele Angelucci, MD

Blood (2020) 136 (Supplement 1): 32.

DOI: https://doi.org/10.1182/blood-2020-140669

Published: 2020

Journal Articles

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Raynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, MD, Didier Blaise, MD, Emanuele Angelucci, Luca Castagna, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MDPhD, Massimo Martino, Friedrich Stoelzel, PD, MD, Gesine Bug, Yves Chalandon, MD, Benedetto Bruno, MD, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Eolia Brissot, MDPhD, Bipin N. Savani, MD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 9.

DOI: https://doi.org/10.1182/blood-2020-140657

Published: 2020

NARROW

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients

Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis

Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT

Bone Marrow Multiparametric Magnetic Resonance Imaging with Texture Analysis for Follow-up of Advanced Stage Myelofibrosis after Transplantation

Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only